Aratana Therapeutics announces study results for AT-016

Aratana Therapeutics, Inc. has received top-line pivotal field effectiveness study results for AT-016, an investigational adipose-derived allogeneic stem cell therapeutic candidate for the control of clinical signs associated with osteoarthritis.

On December 14, 2017, Aratana’s license partner responsible for the development of AT-016 shared the results of a pivotal study, which did not achieve protocol-defined efficacy success criteria. As part of Aratana’s exclusive commercial license for dogs with osteoarthritis in the United States, Aratana had funded the clinical study and other work. Aratana anticipates that after its license partner has further evaluated the study results, the parties will determine if the collaboration to bring the therapeutic to market will continue.

“Recently, the focus has been on the commercialization of our three FDA-approved pet therapeutics ENTYCE, NOCITA, and GALLIPRANT,” explained Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics. “However, Aratana continues to invest in a pipeline of development-stage therapeutic candidates. While we are disappointed with this individual study result, we have had our successes and will continue to execute on our pet therapeutics business model.”